HK1080456A1 - N-substituted hydromorphones and the use thereof - Google Patents

N-substituted hydromorphones and the use thereof

Info

Publication number
HK1080456A1
HK1080456A1 HK05111890A HK05111890A HK1080456A1 HK 1080456 A1 HK1080456 A1 HK 1080456A1 HK 05111890 A HK05111890 A HK 05111890A HK 05111890 A HK05111890 A HK 05111890A HK 1080456 A1 HK1080456 A1 HK 1080456A1
Authority
HK
Hong Kong
Prior art keywords
formula
hydromorphones
substituted
substituted hydromorphones
compounds
Prior art date
Application number
HK05111890A
Other languages
English (en)
Inventor
Donald J Kyle
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of HK1080456A1 publication Critical patent/HK1080456A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK05111890A 2002-09-25 2005-12-22 N-substituted hydromorphones and the use thereof HK1080456A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41325402P 2002-09-25 2002-09-25
PCT/US2003/029876 WO2004029059A1 (en) 2002-09-25 2003-09-24 N-substituted hydromorphones and the use thereof

Publications (1)

Publication Number Publication Date
HK1080456A1 true HK1080456A1 (en) 2006-04-28

Family

ID=32043224

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05111890A HK1080456A1 (en) 2002-09-25 2005-12-22 N-substituted hydromorphones and the use thereof

Country Status (19)

Country Link
US (1) US6825205B2 (xx)
EP (2) EP1543010B1 (xx)
JP (2) JP4806190B2 (xx)
KR (1) KR20050074462A (xx)
CN (1) CN100387600C (xx)
AT (1) ATE360633T1 (xx)
AU (1) AU2003272642B2 (xx)
BR (1) BR0314488A (xx)
CA (1) CA2500118C (xx)
CY (1) CY1106697T1 (xx)
DE (1) DE60313478T2 (xx)
DK (1) DK1543010T3 (xx)
ES (1) ES2286461T3 (xx)
HK (1) HK1080456A1 (xx)
MX (1) MXPA05003104A (xx)
NZ (1) NZ538726A (xx)
PT (1) PT1543010E (xx)
WO (1) WO2004029059A1 (xx)
ZA (1) ZA200502174B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
RU2009112685A (ru) 2006-09-20 2010-10-27 Маллинкродт Инк. (Us) Получение замещенных морфинан-6-онов и их солей и промежуточных соединений
AU2007323573A1 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2008070462A2 (en) * 2006-11-22 2008-06-12 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
WO2008109156A2 (en) * 2007-03-06 2008-09-12 Mallinckrodt Inc. Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
ES2586245T3 (es) * 2007-08-09 2016-10-13 Rensselaer Polytechnic Institute Carboxamidas cuaternarias opioides
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US8883817B2 (en) * 2007-10-18 2014-11-11 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US20110112129A2 (en) * 2007-11-26 2011-05-12 Pharmacofore, Inc. Peripheral Phenolic Opioid Antagonist
ES2549904T3 (es) 2008-05-27 2015-11-03 Mallinckrodt Llc Procesos y compuestos para la preparación de normorfinanos
US9458109B2 (en) 2008-09-03 2016-10-04 Mallinckrodt Llc Substituted berbines and processes for their synthesis
JP5977240B2 (ja) 2010-09-21 2016-08-24 パーデュー、ファーマ、リミテッド、パートナーシップ ブプレノルフィン類似体
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
JP6182620B2 (ja) 2013-01-31 2017-08-16 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
US9656962B2 (en) 2013-12-26 2017-05-23 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
JP2017521373A (ja) 2014-05-27 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環モルフィナン及びその使用
WO2015192053A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
EP0306575B1 (en) * 1987-09-10 1992-07-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP1312361A1 (en) * 1996-11-25 2003-05-21 Toray Industries, Inc. Antipruritic agent
WO2001014382A1 (fr) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesiques contenant des derives sel d'ammonium quaternaire comme principe actif

Also Published As

Publication number Publication date
ATE360633T1 (de) 2007-05-15
US20040067973A1 (en) 2004-04-08
CN100387600C (zh) 2008-05-14
DE60313478D1 (de) 2007-06-06
ZA200502174B (en) 2006-05-31
BR0314488A (pt) 2005-08-02
AU2003272642A1 (en) 2004-04-19
ES2286461T3 (es) 2007-12-01
DE60313478T2 (de) 2008-01-03
KR20050074462A (ko) 2005-07-18
NZ538726A (en) 2006-11-30
AU2003272642B2 (en) 2009-07-09
DK1543010T3 (da) 2007-09-17
EP1803724A1 (en) 2007-07-04
EP1543010B1 (en) 2007-04-25
JP2006503850A (ja) 2006-02-02
CN1684967A (zh) 2005-10-19
CA2500118C (en) 2011-04-12
JP4806190B2 (ja) 2011-11-02
JP2011042681A (ja) 2011-03-03
CA2500118A1 (en) 2004-04-08
US6825205B2 (en) 2004-11-30
CY1106697T1 (el) 2012-05-23
WO2004029059A1 (en) 2004-04-08
EP1543010A1 (en) 2005-06-22
PT1543010E (pt) 2007-07-26
MXPA05003104A (es) 2005-05-27

Similar Documents

Publication Publication Date Title
HK1080456A1 (en) N-substituted hydromorphones and the use thereof
DE60329001D1 (en) 8-hydroxychinolinderivate
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
HRP20080175T3 (en) Substituted 2-aminotetralines for the preventive treatment of parkinson's disease
IN2005KO00312A (xx)
GC0000375A (en) Benzodiazepine derivatives as gaba a receptor modulators
UA96777C2 (xx) Фенілпропіонамідні сполуки та їх застосування як опіоїдних агоністів$фенилпропионамидные соединения и их применение как опиоидных агонистов
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
EP1736157A4 (en) MEDIUM AGAINST JUCKREIZ
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
SI1534296T1 (sl) Uporaba cilobradina ali njegovih farmacevtsko sprejemljivih soli za zdravljenje ali preprečevanje odpovedi srca
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
HRP20030696A2 (en) GlyT-1 INHIBITORS
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
EP1210948A4 (en) DRUGS FOR NERVOUS DISEASES
MY139844A (en) 1,2,4-triaminobenzene derivatives and their uses thereof for the prevention, treatment and/or inhibition of disorders of the central nervous system
PL354698A1 (en) Pharmaceutical compound for prevention or treatment of self-immunization based diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110924